Subclinical infection

Teledentistry Market to be Worth $4.80 Billion by 2030 at CAGR 16.13%: Grand View Research, Inc.

Retrieved on: 
Thursday, January 19, 2023
Cloud, Dental care, Disease, Infection, Dental, Radioactive decay, Dentist, COVID-19, Communication, Pandemic, WHO, Government, Safety, Internet, Health, Dentistry, Partnership, Sonicare, Growth, Philip, Application, Patient, Prevalence, Component, Software, Revenue, SAN, LG, Television, USD, Subclinical infection, Video game console, Cryptocurrency

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global teledentistry market size is expected to reach USD 4.80 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global teledentistry market size is expected to reach USD 4.80 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is anticipated to expand at a CAGR of 16.13% from 2022 to 2030.
  • In addition, the leaders in the market are collaborating with each other to enhance the teledentistry solution portfolio.
  • Grand View Research has segmented the global teledentistry market based on component, delivery mode, application, end-use, and region:
    Teledentistry Market - Component Outlook (Revenue, USD Million, 2017 - 2030)
    Teledentistry Market - Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)
    Teledentistry Market - Application Outlook (Revenue, USD Million, 2017 - 2030)

Teledentistry Market to be Worth $4.80 Billion by 2030 at CAGR 16.13%: Grand View Research, Inc.

Retrieved on: 
Thursday, January 19, 2023
Cloud, Dental care, Disease, Infection, Dental, Radioactive decay, Dentist, COVID-19, Communication, Pandemic, WHO, Government, Safety, Internet, Health, Dentistry, Partnership, Sonicare, Growth, Philip, Application, Patient, Prevalence, Component, Software, Revenue, SAN, LG, Television, USD, Subclinical infection, Video game console, Cryptocurrency

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global teledentistry market size is expected to reach USD 4.80 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global teledentistry market size is expected to reach USD 4.80 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is anticipated to expand at a CAGR of 16.13% from 2022 to 2030.
  • In addition, the leaders in the market are collaborating with each other to enhance the teledentistry solution portfolio.
  • Grand View Research has segmented the global teledentistry market based on component, delivery mode, application, end-use, and region:
    Teledentistry Market - Component Outlook (Revenue, USD Million, 2017 - 2030)
    Teledentistry Market - Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)
    Teledentistry Market - Application Outlook (Revenue, USD Million, 2017 - 2030)

Danco Moves to Intervene in Lawsuit Challenging FDA Approval of Mifeprex®

Retrieved on: 
Saturday, January 14, 2023
Nausea, Danco, Mifepristone, Full, Misoprostol, Anemia, Dizziness, Fever, Prostaglandin, Headache, Anaphylaxis, Gestational age, District court, Administration, Syncope, Patient, Bleeding, Vaginal bleeding, Angioedema, FDA, Pregnancy, Weakness, Genetically modified bacteria, Rash, Hematocrit, REMS, Woman, Death, Danco Laboratories, Health care, Internal bleeding, Subclinical infection, Allergy, Douglas v. U.S. District Court ex rel Talk America, Hypovolemic shock, IUD, Sepsis, Medication, Abdominal pain, Prescription, Vomiting, Pharmacy, Leukocytosis, Tachycardia, Diarrhea, Physician, Pharmaceutical industry, Birth control, Vaccine, Dairy product, Medical device, Medicine, Infection

NEW YORK, Jan. 13, 2023 /PRNewswire/ -- Today, Danco Laboratories (Danco) filed a motion to intervene in Alliance for Hippocratic Medicine v. FDA, a lawsuit in which several anti-abortion organizations and four individual physicians asked a federal court to immediately suspend FDA's approval of Mifeprex®.

Key Points: 
  • NEW YORK, Jan. 13, 2023 /PRNewswire/ -- Today, Danco Laboratories (Danco) filed a motion to intervene in Alliance for Hippocratic Medicine v. FDA, a lawsuit in which several anti-abortion organizations and four individual physicians asked a federal court to immediately suspend FDA's approval of Mifeprex®.
  • The lawsuit is also a direct challenge to the FDA approval process for all pharmaceutical products.
  • Danco joins this action to ensure that the FDA approval of Mifeprex® remains in force and people continue to have access to this safe and effective medication.
  • Over 5 million women have used Mifeprex® in the United States since its approval for the termination of early pregnancy in 2000.

Medical Gloves Market Report 2022: Rising Rates of Infectious Diseases and the Establishment of Infection Prevention Standards Bolster Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 19, 2023
Medical Supplies, Health, Latex, Infection, Subclinical infection, Eyeish, Neoprene, AIDS, Clifton Springs Hospital & Clinic, Hospital-acquired infection, Medicine, Surgeon, Risk, LaTeX, Golden Gloves, Projection, Medical glove, Prevalence, Friction, Nitrile, Hepatitis, Diagnosis, Ventilator-associated pneumonia, Research report, 2052: A Global Forecast for the Next Forty Years, Hygiene, US, Allergy, Investment, Crime, Glove, Medical device, Natural rubber, Personal protective equipment, Hospital, Growth

Medical Gloves Market will reach US$ 19.30 Billion by the end of year 2027 according to the publisher.

Key Points: 
  • Medical Gloves Market will reach US$ 19.30 Billion by the end of year 2027 according to the publisher.
  • Medical gloves are disposable and reusable gloves used during medical surgeries and examinations and preferably help to prevent the spread of illness or infections.
  • According to our research report, Worldwide Medical Gloves Market is expected to grow with a double digit CAGR of 7.65% from 2022 to 2027.
  • The raw material market was segmented into latex gloves, Nitrile gloves, vinyl gloves, and Neoprene gloves.

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Retrieved on: 
Wednesday, January 11, 2023
Cryptococcosis, SAB, CLK, TARGET, Merck, New Drug Application, Staphylococcus aureus, FGFR, Regulation of tobacco by the U.S. Food and Drug Administration, Aspergillosis, CHF, PARG, DXR, Mucormycosis, Marketing, BARDA, Growth, Food, Subclinical infection, Patient, Research, ABSSSI, Glioblastoma, Gram-negative bacteria, Ceftobiprole, LR, Pharmaceutical industry, Vaccine, Isavuconazonium, EU

CHF 122 million, exceeding guidance by more than 17%

Key Points: 
  • CHF 122 million, exceeding guidance by more than 17%
    Ad hoc announcement pursuant to Art.
  • Revenue contributions from the antifungal Cresemba and the antibiotic Zevtera are expected to amount to approximately CHF 122 million (full-year 2022 guidance: CHF 98 million – 104 million).
  • David Veitch, Chief Executive Officer, commented: “We achieved significant milestones in 2022 and will continue to focus on delivering on our strategy to drive value creation going forwards.
  • By November 2022, Basilea had entered into three separate transactions with innovative oncology companies.

ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

Retrieved on: 
Monday, December 19, 2022
Drug of last resort, Infection, Peptide, Staphylococcus, Fosfomycin, SOC, Knee, Data monitoring committee, Risk, Daptomycin, APACHE II, MRSA, APACHE, Patient, Mortality, Safety, Campaign, DSMB, Data set, Subclinical infection, Diagnosis, COVID, Pharmaceutical industry, MD

All patients in the DISRUPT study have now been independently adjudicated and the study database has been locked.

Key Points: 
  • All patients in the DISRUPT study have now been independently adjudicated and the study database has been locked.
  • The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the United States in 259 of the planned 348 patients with S. aureus bacteremia, including right-sided endocarditis.
  • Enrollment in the trial was stopped following a review of the pre-specified, interim futility analysis by the independent Data Safety Monitoring Board (DSMB).
  • The company is planning a virtual fireside chat in the first quarter of 2023 for an in-depth review and discussion of the DISRUPT study.

Global High Level Disinfection Services Market Report to 2030 - Players Include Metrex Research, EcoFMR.com, Jani-King and Rentokil Initial - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Chemicals, Plastics, Health, Manufacturing, Other Health, Eyeish, Subclinical infection, Death, Coronavirus, HAP, Hospital-acquired infection, CDC, Virkon, COVID-19, ICU, Disinfectant, Infection, Hospital, Incidence, Prevalence, LANXESS, HLDS, Animal

According to the report published by CDC in 2017, hospital-acquired infections result in more than 99,000 deaths every year.

Key Points: 
  • According to the report published by CDC in 2017, hospital-acquired infections result in more than 99,000 deaths every year.
  • Since these products are needed for disinfection and cleaning of various hospital equipment, therefore, these instances are expected to surge the demand for high level disinfectant services.
  • Furthermore, the sudden outbreak of COVID-19 across the globe is one of the major factors propelling the market growth.
  • The segment growth is majorly driven by the increasing number of hospital-acquired infections and the rising number of people suffering from coronavirus

Global Antimicrobial Resistance Diagnostics Market Report 2023: Availability of Better Diagnostics Tests and Kits Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Health, Biotechnology, AMR, Eyeish, Fungus, Methicillin, Subclinical infection, Bloodstream infections, DRC, Protein, Viral Research and Diagnostic Laboratories, Medication, Bacteria, Public health, Clostridium difficile, Pathogen, Immunoassay, NGS, DNA, Biotechnology, Urinary tract infection, Hospital, DRSP, Microbiology, CD, MRSA, Patient, Staphylococcus aureus, Pneumonia, Infection, Culture, Drug resistance, Catheter, Prevalence, PCR, Healthcare, Vaccine, Antibiotics, Copper

The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.

Key Points: 
  • The Global Antimicrobial Resistance Diagnostics Market size is expected to reach $5.7 billion by 2028, rising at a market growth of 6.1% CAGR during the forecast period.
  • Based on end user, the antimicrobial resistance diagnostics market is segmented into hospitals, diagnostic laboratories, pharmaceutical & biotechnology companies, and others.
  • The diagnostic laboratories garnered a remarkable growth rate in the antimicrobial resistance diagnostics market in 2021.
  • The North America segment procured the maximum revenue share in the antimicrobial resistance diagnostics market in 2021.

Infection Control Global Market Report 2022: Increasing Prevalence of Hospital-Acquired Infections Spurs Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022
Hospitals, General Health, Health, Other Health, Fungus, Infection, Subclinical infection, Ear, Bacteria, Drink, HAI, COVID-19, Skin, Virus, Laboratory, Food, Urinary tract infection, Sneeze, Disinfectant, Patient, PPE, Safety, Parasitism, Eye, Coronavirus, Mask, Hospital, Surge arrester, Sterilization, Product life-cycle theory, Prevalence, Medical device, Growth

The "Infection Control Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infection Control Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global infection control market size reached US$ 22.8 Billion in 2021.
  • The increasing prevalence of hospital-acquired infections (HAI) and chronic medical ailments is one of the key factors driving the growth of the market.
  • The publisher provides an analysis of the key trends in each sub-segment of the global infection control market report, along with forecasts at the global, regional and country level from 2022-2027.

Global Point-of-Care Molecular Diagnostics Market Report 2022-2027: Growing Popularity of mHealth for Allergy Diagnosis Increases Affordability - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 29, 2022
Health, Other Health, Ansoff Matrix, Eyeish, Viral Research and Diagnostic Laboratories, Hospital-acquired infection, SWOT, Subclinical infection, USD, Porter's five forces analysis, Integrative Production Technology for High-Wage Countries, Risk, Academic institution, Infection, Cancer, Personal Software Services, Growth, Software, Intensive care unit, Prevalence, STD, Investment, COVID-19, High-dependency unit, Degenerative disease, Observation, Market development, Geography, Medical device, Hospital, Retail, Medical imaging, Pharmaceutical industry, Attack Surface Analyzer

Increasing Prevalence of Infectious Diseases, Hospital-Acquired Infections (HAIs), and Cancer

Key Points: 
  • Increasing Prevalence of Infectious Diseases, Hospital-Acquired Infections (HAIs), and Cancer
    The Global Point-of-Care Molecular Diagnostics Market is segmented based on Product, Technology, Applications, End-Users, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Point-of-Care Molecular Diagnostics Market.
  • The analyst analyses the Global Point-of-Care Molecular Diagnostics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Point-of-Care Molecular Diagnostics Market.